A single-dose study of CS-1103 for methamphetamine use
Treatments studied
Part of Mental health clinical trials.
This trial tests a single dose of an investigational drug, CS-1103, to see if it is safe and effective for people who use methamphetamine. It may help understand how the drug affects methamphetamine in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old
- You have been diagnosed with methamphetamine use disorder but are not currently trying to quit
- You usually smoke or inject methamphetamine
- You can go without methamphetamine for a short time without serious discomfort
- You have a body mass index between 18 and 30 and weigh at least 56 kg
- You do not have heart disease or serious kidney problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests high-dose lisdexamfetamine (a prescription stimulant) to help people reduce or stop methamphetamine use. It also uses “contingency management” (rewards tied to meeting goals) to encourage treatment participation and lower use.
This study tests whether a high dose of a stimulant medication (lisdexamfetamine, an ADHD medicine) taken over many weeks can help people who have already completed a methamphetamine treatment program to stay off meth, reduce use, or avoid relapse.
This trial tests whether a psychedelic drug called psilocybin can help people cut down or stop using methamphetamine. You'll take the drug in a supervised setting and get support to aim for full abstinence.
This trial tests whether psilocybin (a psychedelic medicine) can help people quit methamphetamine. You'll receive counseling before, during, and after the drug session, and your progress will be followed for several months.
This trial tests whether a single dose of psilocybin (PEX010) combined with therapy can help people stop using methamphetamine or other stimulants. It focuses on safety and early signs of effectiveness.
This study gives HIV-positive people who are doing well on HIV medication a small dose of methamphetamine to see how it affects their virus and immune system. Researchers want to understand if methamphetamine can wake up hidden HIV that's not being detected.
Hear when a new Methamphetamine Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.